| Epigenomics–BioChain: investment, 201310 acquisition €0.94m ($1.3m) of 217.9k new shares as part of strategic collaboration |
2013-10-28 |
| Formycon–SEVERAL: investment, 201310–201312 capital increase €9.4m 1.257m new common shares €7.5/share to existing shareholders |
2013-10-28 |
| Genetrix (ES)–SEVERAL: investment, 201310 rights offering + private placement of Sygnis AG €2.7m with 1.02m new shares €2.65/share |
2013-10-28 |
| Hana Pharmaceuticals–Paion: remimazolam, 201310– license excl €1m upfront + €2m milestones + 10% royalties for dev + manuf + commerc in Korea |
2013-10-28 |
| Biotest–SEVERAL: credit, 201310– placing of €210m notes in different tranches to more than 70 investors |
2013-10-24 |
| Merck (DE)–Polyplus-transfection: transfection reagents, 201310– license + supply agreem €na for PEI-based transfection reagents incl PEIpro |
2013-10-24 |
| Polyplus-transfection–Image Box: public relations, 201310 service existent by Image Box PR |
2013-10-24 |
| Celesio–McKesson: investment, 201310– acquisition €6.1b with acqu of 50.01% shares from Haniel + cash tender offer for all remaining shares €23/share |
2013-10-23 |
| Chem Tech Research–Apeptico: proteomic database, 201310– license to Pepbase therapeutic protein database for C-TRI |
2013-10-23 |
| F-Star Alpha–F-Star: cancer drugs, 201310– license excl to FS102 + Fcab + mAb2 technologies against up to 22 cancer targets |
2013-10-23 |
| F-Star Alpha–SEVERAL: investment, 201401 financing round Series A €9.4m incl Atlas Venture + Aescap + TVM + SR One + MP Healthcare + MS Ventures |
2013-10-23 |
| Boehringer–Beactica: drug discovery services, 201310– collab expansion €na fragment-based drug discovery services for oncology-relevant kinases |
2013-10-22 |
| Finox–SEVERAL: investment, 201310 capital increase CHF22m incl CHF12m from majority shareholder Willy Michel + CHF10m from BV Group |
2013-10-22 |
| Heraeus–Curetis: molecular diagnostics, 201310 collab existent co-developm + co-marketing of Unyvero i60 ITI application |
2013-10-22 |
| Roche–Samsung: biopharmaceuticals, 201310– supply €na long-term strategic contract manufacturing agreem with Samsung BioLogics |
2013-10-22 |
| Zivak Technologies–Tecan: automated liquid handling, 201310 supply Cavro Omni Robot for use with clinical Dx HPLC + LC-MSMS systems |
2013-10-22 |
| AstraZeneca–Evotec: kidney disease drugs, 201310– license + collab agreem €na giving AZ access to selected series of molecules to treat CKD |
2013-10-21 |
| Clovis Oncology–Qiagen: molecular companion diagnostics, 201310– collab developm of therascreen EGFR RGQ PCR Kit for CO-1686 |
2013-10-21 |
| Mérieux–MC Services: public relations, 201310 service existent for Transgene SA |
2013-10-21 |
| Austria (govt)–Biocom: publishing, 201310 supply service with regard to Vienna Life Science Report 2013/14 to LISAvienna by Biocom |
2013-10-17 |
| Biodesy–Roche: investment, 201310 financing round Series A totalling $15m incl Roche Venture Fund |
2013-10-17 |
| Biodesy–SEVERAL: investment, 201310 financing round Series A $15m from 5AM Ventures + Pfizer Venture Investments + Roche Venture Fund |
2013-10-17 |
| Boehringer–Vector Capital: drug discovery s/w, 201310– supply Certara D360 as drug discovery platform in Ridgefield + Biberach + Vienna |
2013-10-17 |
| Suzhou SJ Biomaterials–Scienion: print/spotting technology, 201310– distribution of Scienion products in China by Suzhou SJ Biomaterials Co Ltd |
2013-10-17 |
| Sygnature Discovery–Proteros: drug discovery services, 201310– collab strategic alliance to offer integrated services incl X-ray structure analysis |
2013-10-17 |
| Merck (DE)–Firefly BioWorks: miRNA research assays, 201310– distribution ww of SmartRNAPlex assay by EMD Millipore |
2013-10-16 |
| Photonics Healthcare–Bavaria (govt): investment, 201310 1st financing round led by HTGF + Bayern Kapital |
2013-10-16 |
| Photonics Healthcare–High-Tech Gründerfonds: investment, 201310 1st financing round led by HTGF + Bayern Kapital |
2013-10-16 |
| Photonics Healthcare–SEVERAL: investment, 201310 1st financing round led by HTGF + Bayern Kapital |
2013-10-16 |
| AstraZeneca–Auven Therapeutics: antibody-drug conjugates, 201310– collab of ADC Therapeutics and MedImmune which acquired Spirogen |
2013-10-15 |
| Auven Therapeutics–AstraZeneca: investment, 201310 acquisition 100% of Spirogen Ltd for $200m upfront + $240 milestones by MedImmune |
2013-10-15 |
| Auven Therapeutics–AstraZeneca: investment, 201310 investment $20m in ADC Therapeutics by MedImmune matched by majority shareholder Auven Therapeutics |
2013-10-15 |
| CV genes-at-target project–EU (govt): grant, 2013– FP7 grant €5.75m to investigate genomic risk loci for CAD + stroke |
2013-10-15 |
| CV genes-at-target project–Evotec: genomic drug target discovery, 2013– collab European ScreeningPort is partner in FP7 project |
2013-10-15 |
| CV genes-at-target project–Genedata: genomic drug target discovery, 2013– collab Genedata is partner in FP7 project |
2013-10-15 |
| CV genes-at-target project–Univ Lübeck: genomic drug target discovery, 2013– collab Univ of Lübeck is partner in FP7 project |
2013-10-15 |
| Immatics–SEVERAL: investment, 201310 financing round Series D 1st tranche €12m of €34m round Hopp + Strüngmann + Wellington Partners + MIG Funds |
2013-10-15 |
| Bayer–BioInvent: antibody library, 201310 license €na extension + broadening to n-CoDeR libraries for development of therapeutic antibodies |
2013-10-14 |
| Novartis–ImmunoGen: ADC technology, 201310– license to use technology against a cancer target under collab agreem from 2010 |
2013-10-11 |
| Cytos Biotechnology–SEVERAL: investment, 201310–201311 capital increase CHF24.3m 8.1m shares CHF3/share to Abingworth + Amgen + venBio + Aisling et al |
2013-10-10 |
| Bayer–RWTH Aachen: bioinformatics, 201310– collab founding of Joint Research Center on Computational Biomedicine by BTS + RWTH |
2013-10-09 |
| Bayer–Sysmex: molecular companion diagnostics, 201310– collab master agreem for developm of blood-based CDx for cancer drugs by Sysmex Inostics |
2013-10-09 |
| Sartorius–PERSON: investment, 201310 existent family of the late Horst Satorius owns 50.09% bound by last will of Horst Satorius |
2013-10-09 |
| Schott–Sony: slides, 201310 collab developm + marketing of glass-plastic hybrid cell imaging slide |
2013-10-07 |
| JnJ–CureVac: vaccine technology, 201310– collab + license €na use of RNActive technology for developm of mRNA-based influenza vaccine with Crucell |
2013-10-03 |
| Merus–Akampion: public relations, 201310 service existent by Akampion |
2013-10-03 |
| Acino–Avista Capital: investment, 201310– public tender offer CHF398m with CHF115/share by Avista Capital Partners + Nordic Capital |
2013-10-02 |
| Acino–Nordic Capital: investment, 201310– public tender offer CHF398m with CHF115/share by Avista Capital Partners + Nordic Capital |
2013-10-02 |
| Acino–SEVERAL: investment, 201310– public tender offer CHF398m with CHF115/share by Avista Capital Partners + Nordic Capital |
2013-10-02 |
| Polymedco–Epigenomics: molecular diagnostics, 201310– collab joint commercialisation of Epi proColon test in North America |
2013-10-02 |
| Findeisen Laborbedarf–Omnilab (DE): investment, 201310 acquisition of Findeisen Laborbedarf GmbH by Omnilab-Laborzentrum GmbH & Co KG |
2013-10-01 |
| Innovative Medicines Initiative–EU (govt): grant, 201310– funding €8m for GETREAL project by IMI of €16.3m total cost |
2013-10-01 |
| Labfolder–SEVERAL: investment, 201310 seed financing round € high 6-digit incl Vogel Ventures + VC Fonds Technologie Berlin |
2013-10-01 |
| SYMPATH project–EU (govt): grant, 201310–201709 FP7 grant €5.89m out of total budget €7.69m to develop Parkinson vaccine |
2013-10-01 |
| Dualsystems Biotech–SEVERAL: investment, 201309 financing round Series C from existing + new investors |
2013-09-30 |
| Roche–Activiomics: mass spectrometry services, 201309 supply services recent partner is Genentech |
2013-09-30 |
| Analytik Jena–Endress+Hauser: investment, 201309–201603 mandatory offer for remaining 52.67% of shares for €13.75/share |
2013-09-27 |
| Analytik Jena–PERSON: investment, 201309 existent founder + CEO Klaus Berka owns 9.93% |
2013-09-27 |
| Panasonic–Kohlberg Kravis Roberts: investment, 201309– acquisition $1.67b of 80% share in Panasonic Healthcare Co Ltd by KKR |
2013-09-27 |
| Merck (DE)–Ablynx: Nanobodies, 201309– collab co-discovery + co-developm Nanobodies extension Merck Serono |
2013-09-26 |
| Panoptes Pharma–4SC: investment, 201309 4SC Discovery receives 24.9% share in Panoptics as part of license for PP-001 |
2013-09-26 |
| Panoptes Pharma–4SC: PP-001, 201309– license for inflammatory eye diseases against 24.9% share in Panoptes plus milestones + royalties |
2013-09-26 |
| Panoptes Pharma–SEVERAL: investment, 201309 seed financing round €1.2m from aws-Life Science Austria + private investors |
2013-09-26 |
| Indivumed–Sysmex: investment, 201309–201310 acquisition of 100% of Inostics GmbH + its subsidiary Inostics Inc by Sysmex Corp |
2013-09-25 |
| Roche–Pacific Biosciences: SMRT technology, 201309– collab ww excl $35m upfront developm + manufacture products for clinical use for Roche Diagnostics |
2013-09-25 |
| Partec–Sysmex: investment, 201309 acquisition of Partec GmbH by Sysmex Corp |
2013-09-24 |
| Myelo Therapeutics–Berlin (govt): investment, 201309 financing round Series A incl VC Fonds Technologie Berlin |
2013-09-23 |
| Myelo Therapeutics–Eckert Wagniskapital: investment, 201309 financing round Series A incl Eckert Wagniskapital und Frühphasenfinanzierung GmbH |
2013-09-23 |
| Myelo Therapeutics–JSC Valenta Pharmaceuticals: investment, 201309 financing round Series A incl JSC Valenta Pharmaceuticals |
2013-09-23 |
| Myelo Therapeutics–SEVERAL: investment, 201309 financing round Series A from VC Fonds Technologie Berlin + Eckert Wagniskapital + JSC Valenta |
2013-09-23 |
| Verenium–BASF: investment, 201309–201310 acquisition $52m cash tender offer $4/share by BASF Corporation |
2013-09-20 |
| Bruker–Philips: magnetic particle imaging, 201309 collab co-developm + co-marketing of preclinical MPI system |
2013-09-19 |
| Kyowa Hakko Kirin–Activiomics: mass spectrometry services, 201309– supply extension research services w TIQUAS technology within BioFocus partnership |
2013-09-19 |
| IKFE–Columbia Healthcare Services: investment, 201309 acquisition 100% of IKFE Services GmbH which continues business of bankrupt IKFE Institut |
2013-09-18 |
| MorphoSys–SEVERAL: investment, 201309 private placement €84m with 1.5m new shares €55.76/share to institutional investors |
2013-09-18 |
| Evonik–Genedata: bioinformatics, 201309– collab expansion use of integrated Genedata offering incl Genedata Selector |
2013-09-17 |
| Microstim–SEVERAL: investment, 201309 financing round €500k MVP + HTGF + Fides Finanz-Invest |
2013-09-17 |
| Affimed–MC Services: public relations, 201309 service existent for Affimed Therapeutics AG |
2013-09-16 |
| Rhön-Klinikum–Fresenius: investment, 201309– acquisition of 43 German hospitals for €3.07b by Fresenius Helios ANNOUNCED |
2013-09-13 |
| Evotec–Harvard Univ: drug discovery, 201309– collab €na drug discovery for ALS using iPS cells with HSCI |
2013-09-12 |
| Prairie Technologies–Bruker: investment, 201309 acquisition by Bruker |
2013-09-12 |
| Bayer–MIT: personalised cancer drugs, 201309– collab 5y discovery + development using oncogenomics with Broad Institute |
2013-09-10 |
| Roche–Inovio: therapeutic vaccines, 201310– license ww excl $10m upfront + $412.5m milestones for INO-5150 + INO-1080 + use of Cellectra technology |
2013-09-10 |
| Neurodyn–Galantos: galantamine, 201309 acquisition of all assets related to Memogain® formulation of galantamine by Neurodyn |
2013-09-09 |
| ArcherDX–Enzymatics: investment, 201309 acquisition up to $50m in cash + equity + milestones |
2013-09-06 |
| Novartis–Regenerex: cell therapy, 201309– global license + research collab for use of hematopoietic stem-cell based FCRx platform |
2013-09-06 |
| Wilex–Nuclea Biotechnologies: investment, 201309 acquisition 100% of Wilex Inc by Nuclea w repayment $2.5m interfirm loan + $2.5m services + royalties |
2013-09-06 |
| Debiopharm–Go To Market: business consulting, 201309– supply service identification of early-stage in-licensing opportunities on US West Coast |
2013-09-05 |
| Piqur Therapeutics–SEVERAL: investment, 201309 private placement (third seed financing round) |
2013-09-05 |
| Analytik Jena–Endress+Hauser: investment, 201309 capital increase €24.4m incl Endress+Hauser with resulting direct + indirect 47.33% share for E+H |
2013-09-04 |
| Analytik Jena–SEVERAL: investment, 201309 capital increase €24.4m €23.4m net 1.95m new shares €12.5/share exlusively to existent shareholders |
2013-09-04 |
| AstraZeneca–Genedata: bioinformatics, 201309 license existent AstraZeneca using Genedata Screener s/w |
2013-09-04 |
| Lilly–Genedata: bioinformatics, 201309 license existent Eli Lilly using Genedata Screener s/w |
2013-09-04 |
| Perora–High-Tech Gründerfonds: investment, 201309 seed financing round led by HTGF |
2013-09-04 |
| Vertex–Genedata: bioinformatics, 201309 license existent Vertex Pharmaceuticals using Genedata Screener s/w |
2013-09-04 |
| Arsanis–Adimab: therapeutic antibodies, 201309 collab development human MAbs for serious infectious diseases |
2013-09-03 |
| Arsanis–SEVERAL: investment, 201309 financing round Series B $20m led by NeoMed Management |
2013-09-03 |
| BioFire Diagnostics–Mérieux: investment, 201309–201401 acquisition 100% for $540m in cash by bioMérieux |
2013-09-03 |
| Boehringer–Diaxonhit: drug discovery services, 201309– supply service €na discovery of oncology drug targets using SpliceArray platform |
2013-09-03 |
| Horizon Discovery–Sigma-Aldrich: DNA-editing technology, 201309– license non-excl €na use of CompoZr ZFN techn tog w rAAV techn under GENESIS brand |
2013-09-03 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lsus-life-sciences-usa-com.jpg)
1 2 3 ... 34 35 36 ... 53 54 55 
Date![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lse-life-sciences-europe-com.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
